Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Income from Continuing Operations (2023 - 2025)

Historic Income from Continuing Operations for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$35.3 million.

  • Inhibrx Biosciences' Income from Continuing Operations rose 1962.43% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.1 million, marking a year-over-year decrease of 10943.65%. This contributed to the annual value of $1.7 billion for FY2024, which is 80395.57% up from last year.
  • As of Q3 2025, Inhibrx Biosciences' Income from Continuing Operations stood at -$35.3 million, which was up 1962.43% from -$28.7 million recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Income from Continuing Operations registered a high of $1.9 billion during Q2 2024, and its lowest value of -$92.0 million during Q4 2023.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$45.5 million (2023), whereas its average is $139.0 million.
  • As far as peak fluctuations go, Inhibrx Biosciences' Income from Continuing Operations soared by 404884.6% in 2024, and later tumbled by 10154.22% in 2025.
  • Inhibrx Biosciences' Income from Continuing Operations (Quarter) stood at -$92.0 million in 2023, then skyrocketed by 47.96% to -$47.9 million in 2024, then increased by 26.34% to -$35.3 million in 2025.
  • Its Income from Continuing Operations was -$35.3 million in Q3 2025, compared to -$28.7 million in Q2 2025 and -$43.3 million in Q1 2025.